Anaplastic Thyroid Cancer - Pipeline Review, H2 2013


#173800

66pages

Global Markets Direct

$ 2000

In Stock


Global Markets Directs, 'Anaplastic Thyroid Cancer Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Anaplastic Thyroid Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anaplastic Thyroid Cancer. Anaplastic Thyroid Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Anaplastic Thyroid Cancer.
  • A review of the Anaplastic Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Anaplastic Thyroid Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Anaplastic Thyroid Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Anaplastic Thyroid Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Anaplastic Thyroid Cancer Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Anaplastic Thyroid Cancer 7
Anaplastic Thyroid Cancer Therapeutics under Development by Companies 9
Anaplastic Thyroid Cancer Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Anaplastic Thyroid Cancer Therapeutics - Products under Development by Companies 15
Anaplastic Thyroid Cancer Therapeutics - Products under Investigation by Universities/Institutes 16
Companies Involved in Anaplastic Thyroid Cancer Therapeutics Development 17
Plexxikon Inc. 17
Exelixis, Inc. 18
EpiCept Corporation 19
OXiGENE, Inc. 20
Genelux Corporation 21
Anaplastic Thyroid Cancer - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
cabozantinib (s)-malate - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
crolibulin - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
fosbretabulin disodium - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
PLX-4720 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
GLONC-2 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
CLM-3 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
CLM-94 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Anaplastic Thyroid Cancer Therapeutics - Drug Profile Updates 40
Anaplastic Thyroid Cancer Therapeutics - Discontinued Products 58
Anaplastic Thyroid Cancer - Product Development Milestones 59
Featured News & Press Releases 59
Jun 10, 2013: Oxigene Announces Publication Of Final FACT Study Data Of Zybrestat In Patients With Anaplastic Thyroid Cancer In Journal Thyroid 59
Feb 14, 2013: Eisai's Thyroid Cancer Drug Candidate Lenvatinib Obtains FDA Orphan Drug Status 60
Jan 08, 2013: Combination Of Pazopanib And Paclitaxel May Slow Anaplastic Thyroid Cancer, Mayo Clinic Study Shows 60
Sep 17, 2012: OXiGENE Announces Agreement With FDA On Special Protocol Assessment For Phase III Trial Of Zybrestat In Anaplastic Thyroid Cancer 61
Sep 07, 2012: Oxigene To Present Data Showing Importance Of Local Site Pathology Confirmation In Phase II/III Clinical Trial Of Zybrestat In Anaplastic Thyroid Cancer 61
Sep 02, 2012: Azanta Pharma And Lavi Enter Into Agreement To Provide Zybrestat In Israel On Compassionate Use Basis 62
Aug 22, 2012: OXiGENE Expands ZYBRESTAT Named Patient Program With Azanta 63
Oct 31, 2005: FDA Grants ZD6474 (Zactima) Orphan Drug Designation For The Investigation Of Rare Forms Of Thyroid Cancer 63

Appendix 65
Methodology 65
Coverage 65
Secondary Research 65
Primary Research 65
Expert Panel Validation 65
Contact Us 66
Disclaimer 66

Number of Products Under Development for Anaplastic Thyroid Cancer, H2 2013 7
Products under Development for Anaplastic Thyroid Cancer - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Number of Products under Investigation by Universities/Institutes, H2 2013 10
Comparative Analysis by Late Stage Development, H2 2013 11
Comparative Analysis by Mid Clinical Stage Development, H2 2013 12
Comparative Analysis by Early Clinical Stage Development, H2 2013 13
Comparative Analysis by Pre-Clinical Stage Development, H2 2013 14
Products under Development by Companies, H2 2013 15
Products under Investigation by Universities/Institutes, H2 2013 16
Plexxikon Inc., H2 2013 17
Exelixis, Inc., H2 2013 18
EpiCept Corporation, H2 2013 19
OXiGENE, Inc., H2 2013 20
Genelux Corporation, H2 2013 21
Assessment by Monotherapy Products, H2 2013 22
Assessment by Stage and Route of Administration, H2 2013 24
Assessment by Stage and Molecule Type, H2 2013 26
Anaplastic Thyroid Cancer Therapeutics - Drug Profile Updates 40
Anaplastic Thyroid Cancer Therapeutics - Discontinued Products 58
Number of Products under Development for Anaplastic Thyroid Cancer, H2 2013 7
Products under Development for Anaplastic Thyroid Cancer - Comparative Analysis, H2 2013 8
Products under Development by Companies, H2 2013 9
Products under Investigation by Universities/Institutes, H2 2013 10
Late Stage Products, H2 2013 11
Mid Clinical Stage Products, H2 2013 12
Early Clinical Stage Products, H2 2013 13
Pre-Clinical Stage Products, H2 2013 14
Assessment by Monotherapy Products, H2 2013 22
Assessment by Route of Administration, H2 2013 23
Assessment by Stage and Route of Administration, H2 2013 24
Assessment by Molecule Type, H2 2013 25
Assessment by Stage and Molecule Type, H2 2013 26